Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Bionano Genomics, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Leadership changes: the latest reported is R. Erik Holmlin (Form 8-K filed 2026-05-06). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Cvi Investments, Inc. (filed 2026-08-14).
Who is behind it
Bionano Genomics, Inc.: incorporated in Delaware; business address in San Diego, California; industry Laboratory Analytical Instruments (Schedule 13G/A, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- R. Erik Holmlin: Executive Officer, Director (Form D, 2024-07-10)
- Gulsen Kama: Executive Officer (Form D, 2024-07-10)
- David L. Barker: Director (Form D, 2024-07-10)
- Yvonne Linney: Director (Form D, 2024-07-10)
- Albert A. Luderer: Director (Form D, 2024-07-10)
- Hannah Mamuszka: Director (Form D, 2024-07-10)
- Aleksandar Rajkovic: Director (Form D, 2024-07-10)
- Christopher Twomey: Director (Form D, 2024-07-10)
- Kristiina Vuori: Director (Form D, 2024-07-10)
- Vincent Wong: Director (Form D, 2024-07-10)
- Alka Chaubey: Executive Officer (Form D, 2024-07-10)
- Mark Oldakowski: Executive Officer (Form D, 2024-07-10)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Cvi Investments, Inc. | 9.9% |
| Schedule 13G/A, 2026-02-17 | Cvi Investments, Inc. | 9.9% |
| Schedule 13G/A, 2026-02-17 | Lind Global Fund Iii LP | 9.35% |
| Schedule 13G/A, 2025-11-14 | Richard Abbe | 4.99% |
| Schedule 13G/A, 2025-11-14 | Lind Global Fund Iii LP | 9.9% |
| Schedule 13G/A, 2025-11-14 | Iroquois Capital Management, LLC | 4.99% |
| Schedule 13G, 2025-11-13 | Ayrton Capital LLC | 9.99% |
| Schedule 13G, 2025-09-24 | Lind Global Fund Iii LP | 9.9% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-05-06 | R. Erik Holmlin | departed | ||
| Form 8-K, 2026-05-06 | Albert A. Luderer | Chief Executive Officer | appointed |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-07-10 | $20M | $20M |
| Form D, 2024-06-05 | $20M | $20M |
| Form D, 2023-10-27 | $35M | $35M |
Latest IPO step: Bionano Genomics, Inc. filed its final IPO prospectus, ticker BNGO (424B4, 2025-09-16).
IPO filings: 424B4, 2025-09-16, S-1, 2025-09-11; ticker BNGO on Nasdaq Capital Market.
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
Permanent URL:
https://mentionfox.com/who-owns/bionano-genomicsLast updated 2026-10-18
Primary record: Schedule 13G/A, 2026-08-14 · Form D, 2024-07-10 · Form 8-K, 2026-05-06 · 424B4, 2025-09-16
Who owns Bionano Genomics, Inc.? Owners, funding and legal record. MentionFox, 2026-10-18. https://mentionfox.com/who-owns/bionano-genomics